Optimal approach to prevent veno-occlusive disease following hematopoietic stem cell transplantation in children.
作者信息
Hassan Zuzana
出版信息
Pediatr Transplant. 2010 Sep 1;14(6):683-7. doi: 10.1111/j.1399-3046.2010.01311.x. Epub 2010 Mar 28.
Abstract
摘要
相似文献
1
Optimal approach to prevent veno-occlusive disease following hematopoietic stem cell transplantation in children.
Pediatr Transplant. 2010 Sep 1;14(6):683-7. doi: 10.1111/j.1399-3046.2010.01311.x. Epub 2010 Mar 28.
2
How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?
Exp Hematol. 2012 Jul;40(7):513-7. doi: 10.1016/j.exphem.2012.04.004. Epub 2012 Apr 25.
3
Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Expert Rev Hematol. 2012 Jun;5(3):291-302. doi: 10.1586/ehm.12.18.
4
Prophylaxis and treatment of hepatic veno-occlusive disease after pediatric stem cell transplantation.
Haematologica. 2006 Jun;91(6):726B.
5
Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant. 2007 Feb;13(2):206-17. doi: 10.1016/j.bbmt.2006.09.012.
6
Hepatic veno-occlusive disease following peripheral blood stem cell or bone marrow transplantation.
Haematologica. 1999 Jun;84 Suppl EHA-4:40-3.
7
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.
Lancet. 2012 Apr 7;379(9823):1301-9. doi: 10.1016/S0140-6736(11)61938-7. Epub 2012 Feb 23.
8
In brief: Defibrotide (Defitelio) for hepatic veno-occlusive disease.
Med Lett Drugs Ther. 2016 Sep 12;58(1503):120.
9
Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
Pediatr Blood Cancer. 2008 Apr;50(4):831-2. doi: 10.1002/pbc.21425.
10
SOS for veno-occlusive disease: defibrotide prophylaxis.
Lancet. 2012 Apr 7;379(9823):1277-8. doi: 10.1016/S0140-6736(12)60067-1. Epub 2012 Feb 23.
引用本文的文献
1
Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis.
Blood Adv. 2020 May 12;4(9):1998-2010. doi: 10.1182/bloodadvances.2020001748.
2
Defibrotide.
Hosp Pharm. 2016 Nov;51(10):847-854. doi: 10.1310/hpj5110-847.
Zotero 插件